NPM_RARα融合基因阳性急性早幼粒细胞白血病一例并
文献复习
Wu Jiawei;Cheng Hui;Guo Mengqiao;Gong Shenglan;Tang Gusheng;Liu Min;Ding Jing;Zhang Yuesheng;Wang Jianmin;Yang Jianmin
【期刊名称】《白血病·淋巴瘤》 【年(卷),期】2019(028)004
【摘要】Objective To investigate the diagnosis, treatment and prognosis of acute promyelocytic leukemia (APL) with NPM_RARα fusion gene positive. Methods One APL patient with NPM_RARα fusion gene positive who was diagnosed by using morphology, immunology, cytogenetics, molecular biology and multiplex fluorescence in situ hybridization in Changhai Hospital in November 2014 was retrospectively analyzed, and the patient was induced with retinoic acid and treated with DA (daunorubicin + cytarabine) regimen, followed by 4 courses of cytarabine consolidation therapy. Results Abnormal promyelocyte accounted for 0.64 by morphology. And the group of cells expressed myeloperoxidase (MPO), CD13, CD15, CD117, and CD7, CD11c, CD79a, CD123 weakly expressed or not by immunophenotype analysis; karyotype analysis showed 45, XY, t(5;17), 7p-,-16[8]/46, idem,+20[5]/45, idem,-8,+20[2]/46, XY[5]; the fusion gene screening showed that the expression level of NPM_RARα was 416.98% compared with that of APL; molecular complete remission was obtained after the
NPM_RARα融合基因阳性急性早幼粒细胞白血病一例并文献复习
